• Vaccine Name: Canine parvovirus CPMV-PARVO1 protein vaccine
• Target Pathogen: Canine parvovirus
• Target Disease: Canine parvovirus infection
• Vaccine Ontology ID: VO_0011464
• Type: Subunit vaccine
• Status: Research
• Antigen: Canine parvovirus VP2
• VP2 gene engineering:
  • Type: Recombinant protein preparation
  • Description: CPMV–PARVO1 contains a 17-amino acid peptide (DGAVQPDGGQPAVRNER) corresponding to residues 3 to 19 from VP2 of canine parvovirus, inserted between residues 22 and 23 of the S protein of CPMV. Each virion contains 60 copies of this peptide and 1 μg chimera contains approximately 20 ng of peptide. The construction, propagation and purification of CPMV–PARVO1 virions (and wild type CPMV) was carried out. In addition, the virus particles were inactivated by irradiation with UV254 light during the purification, according to the following procedure: after resuspension of the PEG/NaCl pellet and clarification, the concentration of particles was measured by spectrophotometry, and the virus-containing supernatant diluted to 1 mg/ml (Langeveld et al., 2001).
  • Detailed Gene Information: Click Here.
• Immunization Route: Subcutaneous injection

Dog Response

• Vaccination Protocol: Dogs were kept in four groups of five or six animals, A–D, each group in a separate room. Groups A, B and C (six dogs in each) were immunized subcutaneously above the shoulder blades on days 0 and 28 with either CPMV–PARVO1, 3L17–KLH or wild type CPMV, respectively, in Quil-A®/Alhydrogel®. A fourth group (D) of five dogs was left unvaccinated. Inoculation sites were checked daily for adverse reactions (Langeveld et al., 2001).
• Challenge Protocol: On day 42, all 23 dogs were challenged with CPV by the oronasal route [19], by distributing CPV onto their eyes, noses and mouths (1.5 ml/dog). Blood was collected prior to immunization, following immunization (days 28 and 38) and following challenge (day 48 and 57), and sera collected and stored at −20°C. Rectal swabs were performed with cotton wool swab sticks and stored at −20°C prior to analysis for the presence of CPV (Langeveld et al., 2001).
• Efficacy: Dogs immunized with the inactivated CPMV-PARVO1 in adjuvant displayed no clinical signs of disease and shedding of CPV in faeces was limited following CPV challenge (Langeveld et al., 2001).